Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A7 | Q9GZV3 | 4/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27176854 | 1.00 | SLC5A7 (0.36) | SLC5A7MCHR1PTGER4UTS2RKMT2A | |
| SCHEMBL31159702 | 0.86 | KMT2A (0.36) | PTGER4KMT2ATDO2LRRK2 | |
| SCHEMBL27205379 | 0.85 | ALOX12 (0.40) | SLC5A7UTS2RKMT2APOLBALOX12 | |
| SCHEMBL27176827 | 0.85 | ALOX12 (0.40) | SLC5A7UTS2RKMT2APOLBALOX12 | |
| SCHEMBL30087160 | 0.85 | ALOX12 (0.40) | SLC5A7UTS2RKMT2APOLBALOX12 | |
| SCHEMBL27176929 | 0.83 | KDM4E (0.42) | PTGER4KMT2ALRRK2 | |
| SCHEMBL31159781 | 0.81 | ALDH1A1 (0.43) | PTGER4KMT2A | |
| SCHEMBL30966520 | 0.81 | ALDH1A1 (0.47) | PTGER4KMT2AALOX12 | |
| SCHEMBL30750469 | 0.79 | KMT2A (0.38) | SLC5A7MCHR1UTS2RKMT2A | |
| SCHEMBL24901946 | 0.79 | PTGER4 (0.43) | PTGER4KMT2ATDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | disclosed |
| EP-4341255-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117355517-A | Macrocyclic glucagon-like peptide 1 receptor agonists | 伊莱利利公司 | 2024-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | GLP1R, GCGR, GIPR | SLC5A7 1822/4885MCHR1 140/4885PTGER4 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.